# Amino Desk > Independent, evidence-graded guide to peptides and GLP-1 medications for US readers: what each compound is, what human evidence exists, its legal status, reported dosing with sources, safety and cost. Each compound carries an evidence grade from A (strongest human evidence) to D (weakest). A grade is not a statement about safety or legality. Dose figures are reported with their source and are not recommendations. Health pages show a clinical-review status. Please cite the page URL when you use this content. ## Machine access - [JSON API](https://aminodesk.com/api/v1): compounds, pages and search as JSON, no key needed - [OpenAPI description](https://aminodesk.com/api/v1/openapi.json) - MCP server (Streamable HTTP, no sign-in): https://aminodesk.com/mcp - Markdown: add .md to any page URL, or send Accept: text/markdown - [Full text of the library in one file](https://aminodesk.com/llms-full.txt) - [How to use these](https://aminodesk.com/developers) ## Compounds - [5-amino-1MQ](https://aminodesk.com/library/5-amino-1mq.md): Grade D. No legal route. Not a peptide. Blocks an enzyme involved in NAD+ metabolism. Striking results in obese mice, zero published human trials, and a 40-fold spread in the doses people inject. - [Adamax](https://aminodesk.com/library/adamax.md): Grade D. No legal route. Semax with an added carbon cage meant to carry it into the brain. No published human trial. Nearly every claim is borrowed from Semax. - [Adipotide](https://aminodesk.com/library/adipotide.md): Grade D. No legal route. Destroys the blood vessels feeding fat tissue. Produced about 11% weight loss in monkeys and damaged the kidneys of every treated animal at the same doses. - [AHK-Cu](https://aminodesk.com/library/ahk-cu.md): Grade D. Mixed. A copper peptide sold for hair growth. Everything specific to it comes from one 2007 laboratory study on follicles and cells. No human trial. - [AOD-9604](https://aminodesk.com/library/aod-9604.md): Grade B. No legal route. Tested properly and failed. Its 536-person trial found no significant weight loss against placebo. Safety record was clean; the drug simply did not work. - [ARA-290](https://aminodesk.com/library/ara-290.md): Grade B. No legal route. An 11-amino-acid peptide tested for nerve pain in sarcoidosis. Small randomized trials were positive, but no Phase 3 trial was run and development is inactive. - [BPC-157](https://aminodesk.com/library/bpc-157.md): Grade C. 2026 policy. The best-known repair peptide, now legally compoundable. Almost all of its evidence is animal work, and an investigation found most of it came from a single lab. - [BPC-157 + KPV](https://aminodesk.com/library/bpc-157-kpv.md): Grade D. No legal route. BPC-157 and KPV in one vial. Each can be compounded alone under the 2026 policy; the mixed vial cannot, and the pair is untested. - [Cagrilintide (and CagriSema)](https://aminodesk.com/library/cagrilintide.md): Grade B. Investigational. An amylin drug that, paired with semaglutide as CagriSema, produced about 20% weight loss in a large trial. Under FDA review; the FDA says it cannot be compounded. - [CagriSema](https://aminodesk.com/library/cagrisema.md): Grade B. Investigational. Cagrilintide and semaglutide in one weekly injection. About 20% weight loss in its main trial. Under FDA review, with no decision announced when we last checked. - [Cartalax](https://aminodesk.com/library/cartalax.md): Grade D. No legal route. A Russian short peptide sold for cartilage and joint support. The evidence is cell and animal work from the group that developed it. - [Cerebrolysin](https://aminodesk.com/library/cerebrolysin.md): Grade B. Not in the US. A pig-brain peptide mixture approved in over 50 countries but not the US. A Cochrane review of 1,773 stroke patients found no benefit on death and more serious adverse events. - [CJC-1295](https://aminodesk.com/library/cjc-1295.md): Grade C. No legal route. Keeps growth hormone elevated for days after one injection. The entire human record is a 2006 Phase 1 study that measured hormone levels, not results. - [CJC-1295 + ipamorelin](https://aminodesk.com/library/cjc-1295-ipamorelin.md): Grade D. No legal route. The most common growth-hormone pairing. Each part raises growth hormone in short studies; the pair has never been tested together, and neither can be legally compounded. - [CJC-1295 + ipamorelin + tesamorelin](https://aminodesk.com/library/cjc-1295-ipamorelin-tesamorelin.md): Grade D. No legal route. CJC-1295, ipamorelin and tesamorelin in one vial. Three growth hormone releasers at once. Never tested together, and two of the three cannot be compounded. - [Cortagen](https://aminodesk.com/library/cortagen.md): Grade D. No legal route. A Russian short peptide sold for brain and nerve support. The evidence is cell and animal work from the group that developed it. - [Dihexa](https://aminodesk.com/library/dihexa.md): Grade D. No legal route. Sold for memory. No human data of any kind, and the paper describing how it was supposed to work has been retracted. - [DSIP](https://aminodesk.com/library/dsip.md): Grade C. No legal route. A sleep peptide from the 1970s. In July 2026 it was the only one of seven compounds an FDA advisory committee voted against allowing pharmacies to compound. - [Dulaglutide](https://aminodesk.com/library/dulaglutide.md): Grade A. FDA-approved. The weekly GLP-1 sold as Trulicity. Approved for type 2 diabetes, not for weight loss, and the weight lost in its trials was modest. - [Eloralintide](https://aminodesk.com/library/eloralintide.md): Grade B. Investigational. A weekly amylin drug from Lilly. Up to 20% weight loss at 48 weeks in a mid-stage trial of 263 people. Still in Phase 3, so it cannot be prescribed. - [Epitalon](https://aminodesk.com/library/epitalon.md): Grade C. 2026 policy. A four-amino-acid peptide sold for longevity and telomere effects. Legally compoundable in courses since October 2026; the human evidence is old and limited. - [Epitalon + MOTS-c](https://aminodesk.com/library/epitalon-mots-c.md): Grade D. No legal route. Epitalon and MOTS-c in one product. Each can be compounded alone under the 2026 policy; the mixed vial cannot, and the pair is untested. - [FGL](https://aminodesk.com/library/fgl.md): Grade C. No legal route. A fragment of a nerve cell adhesion protein. It improved memory in rats and passed one safety study in 24 healthy men. No trial has tested whether it works in people. - [FOXO4-DRI](https://aminodesk.com/library/foxo4-dri.md): Grade D. No legal route. A designed peptide that clears worn-out cells in aged mice. It has no human trial, no registered study and no human safety data. - [GHK-Cu and the Glow stack](https://aminodesk.com/library/ghk-cu.md): Grade C. Mixed. A copper peptide with genuine evidence in skincare, where it is sold as a cosmetic. The injectable version is a different proposition and awaits FDA review. - [GHK-Cu + BPC-157](https://aminodesk.com/library/ghk-cu-bpc-157.md): Grade D. No legal route. GHK-Cu and BPC-157 in one vial. Untested as a pair, and outside the 2026 policy on two counts. - [GHK-Cu + KPV](https://aminodesk.com/library/ghk-cu-kpv.md): Grade D. No legal route. GHK-Cu and KPV in one vial. Untested as a pair, and outside the 2026 policy on two counts. - [GHRP-2 and GHRP-6](https://aminodesk.com/library/ghrp-2-ghrp-6.md): Grade C. No legal route. Older growth hormone releasers. They work, and they also raise cortisol, prolactin and appetite, which is why clinicians moved on from them. - [GLOW blend](https://aminodesk.com/library/glow-blend.md): Grade D. No legal route. GHK-Cu, BPC-157 and TB-500 in one vial, sold for skin, hair and recovery together. No trial of the mixture exists, and a mixed vial falls outside the 2026 policy. - [Glutathione (injectable)](https://aminodesk.com/library/glutathione.md): Grade C. Compounded. The body's main antioxidant, sold as IV drips for skin and detox. Not FDA-approved, and contaminated compounded batches sent patients to hospital in 2026. - [Gonadorelin](https://aminodesk.com/library/gonadorelin.md): Grade C. Compounded. Synthetic GnRH, sold as an add-on to testosterone therapy to protect fertility. That use has no controlled trial behind it, and the approved brands were discontinued. - [Growth hormone (HGH)](https://aminodesk.com/library/growth-hormone.md): Grade A. FDA-approved. The real thing, approved for deficiency and specific medical conditions. Federal law bars distributing it for anti-aging or bodybuilding, which is most of what it is sought for. - [HCG](https://aminodesk.com/library/hcg.md): Grade A. FDA-approved. Imitates the body's signal to ovulate or to produce testosterone. Approved for fertility and certain cases of low testosterone. Not approved for weight loss, despite the diet industry built on it. - [Hexarelin](https://aminodesk.com/library/hexarelin.md): Grade C. No legal route. A strong growth hormone releaser in short studies, with a catch: the response fades within weeks of regular use. Also raises cortisol and prolactin. Never approved anywhere. - [Humanin](https://aminodesk.com/library/humanin.md): Grade D. No legal route. A protective peptide your own mitochondria make. Human studies measure natural levels only. Nobody has run a trial of giving it to people. - [IGF-1 LR3](https://aminodesk.com/library/igf-1-lr3.md): Grade D. No legal route. A laboratory reagent sold for muscle growth. No human trials at all. The approved IGF-1 drug carries warnings for severe low blood sugar and for malignancy. - [Ipamorelin](https://aminodesk.com/library/ipamorelin.md): Grade C. No legal route. The most popular growth hormone secretagogue, usually sold with CJC-1295. Raises growth hormone reliably. Its only human trial, in post-surgical recovery, failed. - [Khavinson short peptides (9)](https://aminodesk.com/library/khavinson-bioregulators.md): Grade D. No legal route. Nine Russian short peptides, each sold for one organ: Bronchogen, Cardiogen, Chonluten, Crystagen, Livagen, Ovagen, Pancragen, Prostamax and Testagen. No controlled human trial of any of them. - [Kisspeptin](https://aminodesk.com/library/kisspeptin.md): Grade B. Investigational. The hormone that starts puberty. Has real controlled trials in IVF and in low sexual desire, though the version sold online differs from the one studied. - [KLOW blend](https://aminodesk.com/library/klow-blend.md): Grade D. No legal route. The GLOW formula plus KPV: four peptides in a fixed ratio, mostly GHK-Cu by weight. Never tested as a mixture, and outside the 2026 policy. - [KPV](https://aminodesk.com/library/kpv.md): Grade D. 2026 policy. A three-amino-acid peptide taken orally or applied to skin, marketed for gut and skin inflammation. Covered by the 2026 policy, with thin human data. - [L-carnitine (injectable)](https://aminodesk.com/library/l-carnitine.md): Grade B. Mixed. Approved for carnitine deficiency and sold as weight-loss shots. Dozens of trials, mostly oral, show about 1 kg of extra weight loss; the shots themselves are untested. - [Larazotide](https://aminodesk.com/library/larazotide.md): Grade B. No legal route. An oral peptide tested for celiac disease and sold as a gut-repair peptide. Its Phase 3 trial was stopped in 2022 when interim results showed it was unlikely to succeed. - [Lipo-C and Lipo-C + B12](https://aminodesk.com/library/lipo-c.md): Grade D. Compounded. A compounded shot of methionine, inositol and choline, usually with B12. Not a peptide. We found no controlled trial showing it causes weight loss. - [Liraglutide](https://aminodesk.com/library/liraglutide.md): Grade A. FDA-approved. The older, daily GLP-1 injection, sold as Saxenda and Victoza. About 8% average weight loss in its main trial, and the first GLP-1 with an approved generic for weight loss. - [LL-37 (cathelicidin)](https://aminodesk.com/library/ll-37.md): Grade C. No legal route. The body's own antimicrobial peptide. Tested only as a wound treatment, with one positive and one negative trial; the injectable version sold online is unstudied. - [Mazdutide](https://aminodesk.com/library/mazdutide.md): Grade B. Not in the US. A weekly weight-loss injection approved in China in 2025. Real approval, real trials, but no route to it in the United States. - [Melanotan I (afamelanotide, Scenesse)](https://aminodesk.com/library/melanotan-i.md): Grade A. FDA-approved. Approved as Scenesse, a clinic-inserted implant for a rare disorder that makes sunlight painful. Not approved for tanning, and the injectable powder sold online is not the approved product. - [Melanotan II](https://aminodesk.com/library/melanotan-ii.md): Grade C. No legal route. Darkens skin and raises libido. Also associated with changes to moles and reports of melanoma. No legal route; FDA review due February 2027. - [Methylene blue](https://aminodesk.com/library/methylene-blue.md): Grade A. FDA-approved. An approved prescription drug for one rare blood condition, now sold in dropper bottles for focus. Carries a boxed warning for serotonin syndrome with SSRIs and similar drugs. - [MK-677 (ibutamoren)](https://aminodesk.com/library/mk-677.md): Grade B. No legal route. An oral drug, not a peptide, that raises growth hormone. Real trials: a little more lean mass, no gain in strength, higher blood sugar, and one trial stopped over heart failure. - [MOTS-c](https://aminodesk.com/library/mots-c.md): Grade D. 2026 policy. Encoded in mitochondrial DNA and marketed for metabolism and energy. Newly compoundable, with the human evidence still to come. - [N-acetyl Selank amidate](https://aminodesk.com/library/n-acetyl-selank.md): Grade D. No legal route. Selank with both ends capped to resist breakdown. The modified version has no clinical study of its own. - [N-acetyl Semax amidate](https://aminodesk.com/library/n-acetyl-semax.md): Grade D. No legal route. Semax with both ends capped to resist breakdown. The modified version has no clinical study of its own. - [NAD+](https://aminodesk.com/library/nad.md): Grade D. Compounded. A coenzyme central to cell metabolism. Oral precursors have human trials behind them; the injected and IV versions sold by clinics largely do not. - [Oxytocin](https://aminodesk.com/library/oxytocin.md): Grade B. Mixed. Approved as a hospital drug for labor. The nasal spray sold for bonding and mood is not approved for anything, and its largest trial found no benefit. - [P21 (P021)](https://aminodesk.com/library/p21.md): Grade D. No legal route. A fragment of a nerve growth factor with good mouse data on memory. No human trial, and the one independent attempt to repeat its core effect failed. - [PE-22-28](https://aminodesk.com/library/pe-22-28.md): Grade D. No legal route. A seven-amino-acid peptide with antidepressant-like effects in rodents. No human trial has been completed or registered. - [PEG-MGF](https://aminodesk.com/library/peg-mgf.md): Grade D. No legal route. A long-acting version of a growth factor that muscle makes after exercise. Everything claimed comes from cells and animals. No human trial of the injected product exists. - [Pentosan polysulfate](https://aminodesk.com/library/pentosan-polysulfate.md): Grade A. Mixed. Not a peptide. The capsule is approved for bladder pain from interstitial cystitis and carries an eye warning with long-term use. The joint injections clinics sell are not approved. - [Pinealon](https://aminodesk.com/library/pinealon.md): Grade D. No legal route. A Russian three-amino-acid 'bioregulator' sold for memory and brain aging. Evidence is cell and rodent work from one research group. - [PNC-27](https://aminodesk.com/library/pnc-27.md): Grade D. No legal route. Sold online as a cure for all cancers. The FDA warned consumers not to use it after finding bacteria in samples. It has only been studied in cells. - [Progesterone](https://aminodesk.com/library/progesterone.md): Grade A. FDA-approved. A hormone, not a peptide. The capsules are approved to protect the uterus during estrogen therapy after menopause and to restart absent periods. Contains peanut oil. - [PT-141 (bremelanotide, Vyleesi)](https://aminodesk.com/library/pt-141.md): Grade A. FDA-approved. The research name for bremelanotide, approved as Vyleesi for low sexual desire in premenopausal women. Raises blood pressure briefly after each dose and can darken patches of skin. - [PT-141 + oxytocin](https://aminodesk.com/library/pt-141-oxytocin.md): Grade D. Mixed. PT-141 and oxytocin in one product. Both ingredients are in approved drugs, but the combination has no trial and no label. - [Rapamycin (sirolimus)](https://aminodesk.com/library/rapamycin.md): Grade B. FDA-approved. A transplant drug, not a peptide, taken off-label for longevity. Its one year-long trial in healthy adults missed its main goal. Carries a boxed warning for immune suppression. - [Retatrutide](https://aminodesk.com/library/retatrutide.md): Grade B. Investigational. Eli Lilly's experimental triple-hormone injection, with strong Phase 3 results and a planned FDA filing. Available only through clinical trials right now. - [Retatrutide + cagrilintide](https://aminodesk.com/library/retatrutide-cagrilintide.md): Grade D. No legal route. Retatrutide and cagrilintide in one product. Two unapproved weight-loss drugs from rival companies. No trial has combined them, and neither can be prescribed. - [Selank](https://aminodesk.com/library/selank.md): Grade C. No legal route. Approved in Russia as an anti-anxiety nasal spray, with small trials suggesting benzodiazepine-like effect without sedation. No Western trials and no US route. - [Semaglutide](https://aminodesk.com/library/semaglutide.md): Grade A. FDA-approved. The most studied weight-loss drug available. Sold as Wegovy and Ozempic, as a weekly injection or a daily pill. Large trials behind it and a known side-effect profile. - [Semax](https://aminodesk.com/library/semax.md): Grade C. 2026 policy. A nasal peptide from Russian research, now legally compoundable as a nasal spray. Marketed for focus and recovery after stroke. - [Semax + Selank](https://aminodesk.com/library/semax-selank.md): Grade D. No legal route. Semax and Selank in one product. Never tested together, and a mixed product falls outside the 2026 policy. - [Sermorelin](https://aminodesk.com/library/sermorelin.md): Grade B. Compounded. Signals your pituitary to release its own growth hormone rather than supplying hormone directly. Prescribed and compounded legally, with modest evidence for the uses it is marketed for. - [SLU-PP-332](https://aminodesk.com/library/slu-pp-332.md): Grade D. No legal route. The "exercise pill." Mice ran 70% longer and obese mice lost weight. No human has been given it in a registered trial. - [SNAP-8](https://aminodesk.com/library/snap-8.md): Grade C. Mixed. A cosmetic peptide in wrinkle creams. The wrinkle-reduction figure comes from the manufacturer. No independent study has tested it on its own. - [SS-31 (elamipretide, Forzinity)](https://aminodesk.com/library/ss-31.md): Grade B. FDA-approved. Approved in 2025 for Barth syndrome, a rare mitochondrial disease, on a 12-patient trial that missed its main goals. Sold online for energy and longevity, which have not been tested. - [Survodutide](https://aminodesk.com/library/survodutide.md): Grade B. Investigational. A weekly GLP-1 and glucagon injection with about 13% average weight loss in a 76-week Phase 3 trial. Not approved; stomach side effects were common. - [TB-500](https://aminodesk.com/library/tb-500.md): Grade D. 2026 policy. Related to thymosin beta-4 and usually paired with BPC-157. Legally compoundable since October 2026; human evidence for healing is essentially absent. - [Tesamorelin](https://aminodesk.com/library/tesamorelin.md): Grade A. FDA-approved. The only growth-hormone-type drug with a current FDA approval. Narrowly approved to reduce excess abdominal fat in people with HIV and lipodystrophy; the fat returns if you stop. - [Tesamorelin + ipamorelin](https://aminodesk.com/library/tesamorelin-ipamorelin.md): Grade D. No legal route. tesamorelin and ipamorelin in one vial. One part is an approved drug for a narrow use; the other cannot be compounded. Never tested together. - [Tesofensine](https://aminodesk.com/library/tesofensine.md): Grade B. Investigational. A pill, not a peptide. About 9% weight loss in a 24-week trial, alongside raised heart rate and blood pressure. Never FDA-approved. - [Testosterone](https://aminodesk.com/library/testosterone.md): Grade A. FDA-approved. A steroid hormone, not a peptide, and a controlled substance. Approved for men with low testosterone tied to a medical condition. Raises blood pressure and can reduce fertility. - [Thymalin](https://aminodesk.com/library/thymalin.md): Grade C. Not in the US. A calf-thymus extract registered as an immune drug in Russia. The longevity claim rests on one unblinded cohort from its developers that nobody has repeated. - [Thymogen](https://aminodesk.com/library/thymogen.md): Grade C. Not in the US. A two-amino-acid peptide registered as an immune drug in Russia since 1990. Russian evidence-based medicine sources list it as lacking proven efficacy. - [Thymosin alpha-1](https://aminodesk.com/library/thymosin-alpha-1.md): Grade B. Not in the US. An immune peptide approved abroad as Zadaxin for hepatitis B. An FDA advisory committee voted 17 to 4 against allowing it to be compounded. - [Thymulin](https://aminodesk.com/library/thymulin.md): Grade D. No legal route. A thymus hormone that needs zinc to work. Human studies show zinc deficiency lowers it and zinc restores it. Injecting the peptide has no modern trial behind it. - [Tirzepatide](https://aminodesk.com/library/tirzepatide.md): Grade A. FDA-approved. Acts on two hormone receptors instead of one. Sold as Zepbound and Mounjaro. Produced some of the largest weight reductions seen in obesity trials. - [Tirzepatide + BPC-157](https://aminodesk.com/library/tirzepatide-bpc-157.md): Grade D. No legal route. Tirzepatide and BPC-157 in one product. An approved weight-loss drug mixed with an animal-tested peptide. The claim that BPC-157 eases the side effects is untested. - [Vesugen](https://aminodesk.com/library/vesugen.md): Grade D. No legal route. A Russian short peptide sold for blood vessel support. The evidence is cell and animal work from the group that developed it. - [Vilon](https://aminodesk.com/library/vilon.md): Grade D. No legal route. A Russian short peptide sold for immune support and anti-aging. Mouse and cell studies from its developers, never reproduced by an outside laboratory. - [VIP (aviptadil)](https://aminodesk.com/library/vip.md): Grade C. Compounded. A natural signaling peptide sold as a compounded nasal spray. The evidence for the spray is one small uncontrolled series. The intravenous drug failed its large trial. - [Vitamin B12 injections](https://aminodesk.com/library/vitamin-b12.md): Grade A. FDA-approved. A vitamin, not a peptide. Approved to treat B12 deficiency in people who cannot absorb it. The label lists no use for energy or weight loss when levels are normal. - [Wolverine blend](https://aminodesk.com/library/wolverine-blend.md): Grade D. No legal route. BPC-157 and TB-500 mixed in one vial. Each can be compounded alone under the 2026 policy; the mixed vial cannot, and the combination has never been tested in people. ## Comparisons - [BPC-157 vs TB-500](https://aminodesk.com/compare/bpc-157-vs-tb-500.md): BPC-157 and TB-500 compared: what each is, how much human evidence exists, legal forms under the 2026 policy, and reported dosing. - [Semaglutide vs tirzepatide](https://aminodesk.com/compare/semaglutide-vs-tirzepatide.md): Wegovy vs Zepbound compared: the head-to-head trial result, pill vs injection, heart outcomes, approved uses and current cash prices. ## Guides - [How to mix and inject a peptide safely](https://aminodesk.com/guides/mixing-and-injecting.md): Step-by-step guide to reconstituting a prescription peptide vial, drawing a dose, injecting under the skin, storage and needle disposal, with CDC, FDA and label sources. - [Protein and muscle on GLP-1 medications](https://aminodesk.com/guides/protein-on-glp-1.md): How much of the weight lost on semaglutide and tirzepatide is muscle, and the protein and strength-training targets from the 2025 joint medical society advisory. - [GLP-3, GLP1-R, reta: what seller code names mean](https://aminodesk.com/guides/seller-code-names.md): GLP-3 is not a real hormone. What codes like GLP-3, GLP1-R, GLP1-T and reta refer to, why sellers use them, and what FDA warning letters say. - [Syringes, needles and supplies: a plain guide](https://aminodesk.com/guides/supplies.md): Insulin syringe sizes and markings, needle gauge and length, alcohol pads and sharps containers explained for people with a prescription vial. ## By goal - [Peptides for energy and longevity](https://aminodesk.com/goals/energy-and-longevity.md): NAD+, MOTS-c, Epitalon, SS-31 and others sold for energy and aging: what has been tested in people and what you can legally get. - [Peptides for focus and mood](https://aminodesk.com/goals/focus-and-mood.md): Semax, Selank, dihexa, methylene blue and others sold for cognition and anxiety: evidence, legal status and the drug interaction to know. - [Peptides for hormones and fertility](https://aminodesk.com/goals/hormones-and-fertility.md): HCG and kisspeptin: what each is approved or studied for in fertility and testosterone care. - [Peptides for injury and tissue repair](https://aminodesk.com/goals/injury-recovery.md): BPC-157, TB-500, KPV and others sold for healing: what the human evidence shows and what the October 2026 policy changed. - [Peptides for muscle and growth hormone](https://aminodesk.com/goals/muscle-and-growth-hormone.md): Sermorelin, ipamorelin, CJC-1295, tesamorelin and growth hormone compared by evidence and legal status. What raises growth hormone and what that has been shown to do. - [Peptides for sexual health](https://aminodesk.com/goals/sexual-health.md): PT-141 (Vyleesi), kisspeptin, Melanotan II and HCG: which is FDA-approved, for whom, and what the trials measured. - [Peptides for skin and hair](https://aminodesk.com/goals/skin-and-hair.md): GHK-Cu, glutathione and the melanotans: which have human evidence for skin, which are creams versus injections, and the safety problems to know about. - [Peptides for sleep](https://aminodesk.com/goals/sleep.md): DSIP, sermorelin and Epitalon are sold for sleep. What the evidence shows, and why DSIP was the one peptide an FDA committee voted down in 2026. - [Peptides for weight loss: what works and what is legal](https://aminodesk.com/goals/weight-loss.md): Which weight-loss peptides have real evidence, which are still experimental, and which you can legally get. Semaglutide, tirzepatide, retatrutide and more. ## Reference - [Peptide reconstitution calculator](https://aminodesk.com/calculator.md): Free peptide reconstitution calculator: enter vial size, water added and your prescribed dose to get insulin syringe units, mL and doses per vial. - [What it costs](https://aminodesk.com/costs.md): GLP-1 and peptide pricing in November 2026: manufacturer-direct cash prices by dose, compounded ranges, and how teaser pricing works. - [Find a compound](https://aminodesk.com/finder.md): Filter peptides and GLP-1s by what you are trying to do and by whether there is a lawful way to get them, with an evidence grade on every result. - [How to vet a provider](https://aminodesk.com/providers.md): Five checks to run on any telehealth provider selling GLP-1s or peptides, the red flags, and what the FDA's warning letters reveal. - [Blends and stacks](https://aminodesk.com/stacks.md): Wolverine, Glow, KLOW and the retatrutide weight-loss stacks: what is in each, the compounding rule that excludes mixed vials, and why no combination has been tested. - [Regulation tracker](https://aminodesk.com/tracker.md): A dated timeline of FDA and HHS actions on peptides and GLP-1 medications in the United States, with a source on every entry. ## Optional - [About Amino Desk](https://aminodesk.com/about.md): Who Amino Desk is, what it covers, how it makes money and what it will not do. - [Affiliate disclosure](https://aminodesk.com/affiliate-disclosure.md): How Amino Desk earns money from provider links, which providers qualify, and how paid links are labeled. - [How we use AI](https://aminodesk.com/ai.md): Where Amino Desk uses AI tools in research, writing and video, and where a person makes the call. - [API and AI access](https://aminodesk.com/developers.md): Amino Desk for AI assistants and developers: Markdown pages, a free JSON API and an MCP server for our evidence-graded peptide and GLP-1 reference. - [Disclaimers](https://aminodesk.com/disclaimers.md): What Amino Desk is and is not: general information, not medical advice, how dosing information should be read, and what to do in an emergency. - [Editorial policy](https://aminodesk.com/editorial-policy.md): How Amino Desk sources, grades evidence, reports dosing, handles corrections and separates editorial from revenue. - [Privacy policy](https://aminodesk.com/privacy.md): What information Amino Desk collects, how it is used, who processes it and how to have it removed.